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To the editor: 
 
Airway hyperresponsiveness (AHR) to adenosine has proven to be a good marker for 
eosinophilic airway inflammation in asthma and can be used to monitor disease activity and 
therapeutic effectiveness of inhaled corticosteroids (ICS) (1–3). Adenosine is usually 
administered by nebulization of adenosine monophosphate (AMP) but the highest feasible 
concentration of AMP often fails to induce sufficient bronchoconstriction in subjects with 
asthma (4,5). We studied whether this limitation can be resolved by administering adenosine 
as dry powder formulation. We have previously demonstrated the feasibility of this new 
bronchial provocation method in a small proof-of-concept study (6). The aim of the present 
study was to further validate the dry powder adenosine provocation test in a larger cohort of 
subjects with asthma.  
 
Data were obtained from subjects recruited for the OLIVIA study (clinical trial number: 
NCT01741285, www.clinicaltrials.gov). Sixty current or ex-smokers with asthma (34 
females, 26 males) with FEV1 ≥50% predicted, who did not use ICS for at least four weeks, 
underwent provocations with both AMP and dry powder adenosine as baseline measurements 
on subsequent visits (1–2 weeks apart), in addition to blood sampling, spirometry, body 
plethysmography, impulse oscillometry (IOS) and multiple breath nitrogen washout (MBNW) 
measurements. Their mean (±SD) age was 45±12 years and baseline FEV1 89±16 %predicted.  
 
AMP was administered by nebulization of doubling concentrations (0.04–320 mg/mL). Dry 
powder adenosine was administered with an investigational inhaler in doubling doses (0.04–
80 mg) (6,7). We determined the provocative concentration (PC20) of AMP and dose (PD20) 
of adenosine causing the forced expiratory volume in 1 s (FEV1) to drop with 20% by log-
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linear interpolation and assessed which clinical characteristics were predictors of these 
parameters. Provocation tests were negative if no 20% drop in FEV1 was reached after 
administration of the highest concentration/dose and values were censored to 640 mg/mL for 
PC20 AMP and 160 mg for PD20 adenosine for analysis. Calculations were performed with the 
base-2 logarithm (log2) of PC20 AMP and PD20 adenosine to reflect the use of doubling dose 
steps and normalize the distribution. 
 
We calculated the agreement between the two tests with Cohen’s kappa and correlation 
analysis. Correlation analysis was also performed to assess associations between subject 
baseline characteristics and PC20 AMP/PD20 adenosine. Associations with a p-value <0.20 
were considered for multiple linear regression analysis, although per baseline measurement 
procedure maximally one (the most significant) predictor was included to prevent 
multicollinearity. Forced entry multiple linear regression analysis was performed to determine 
which parameters independently predict the airway responses.  
 
Forty subjects reached the predefined 20% drop in FEV1 on both AMP and adenosine. Ten 
subjects obtained a positive adenosine test (PD20 5.4–39 mg) but negative AMP test (PC20 
>320 mg/mL), whereas two subjects had a negative adenosine test (PD20 >80 mg) but positive 
AMP test (PC20 143 and 148 mg/mL). Seven subjects did not reach a 20% drop in FEV1 on 
either stimulus. One subject, who had a negative AMP test, experienced severe cough during 
inhalation of dry powder adenosine, leading to early termination of the test. The total 
percentage of non-responders was 30% (18 out of 60) for AMP and 15% (9 out of 59) for 
adenosine. Figure 1A shows PC20 AMP and PD20 adenosine values, clearly illustrating the 
higher responder rate to adenosine. PC20 AMP and PD20 adenosine were strongly correlated 
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(rSp = 0.799; Figure 1B), yet had only a moderate agreement (κ = 0.42), mainly due to the 
larger number of non-responders to AMP.  
 
Baseline variables included in multiple linear regression analysis for PC20 AMP were age, 
smoking status, blood eosinophils, FEV1, residual volume (RV), and the ventilation 
heterogeneity of the conductive lung zone (Scond). For PD20 adenosine these were age, blood 
eosinophils, FEV1, and RV. The models obtained by multiple regression analysis were largely 
similar for PC20 AMP and PD20 adenosine with predictive powers of 34% and 30% 
respectively (Table 1). Only age (AMP and adenosine) and FEV1 (adenosine) were found to 
be independent predictors (p < 0.05). Age and FEV1 were positively associated with both 
PC20 AMP and PD20 adenosine, whereas blood eosinophils and RV exhibited a trend towards 
an inverse association. 
 
The present work shows that bronchial provocation with dry powder adenosine is a suitable 
method for measuring AHR in asthmatic subjects. Moreover, the new test method allowed us 
to administer higher doses, resulting in fewer false negative test results, while the degree of 
AHR to dry powder adenosine correlated well with the degree of AHR to nebulized AMP. 
Despite the greater sensitivity, there were still nine subjects with a negative dry powder 
adenosine provocation test. Although the order of provocation testing was performed non-
randomized with AMP first and dry powder adenosine second one to two weeks later and 
refractoriness has been shown to occur after AMP provocation (8), we consider any remaining 
effect one to two weeks later to be unlikely given the findings of Singh et al. (9). Some 
patients may have developed a component of COPD or asthma-COPD overlap, since this 
study examined current or former smokers. There was, however, no relationship apparent 
between measures of airway obstruction at baseline and PD20 adenosine (e.g. only two out of 
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nine had an FEV1/FVC ratio <70%) or with their smoking status (four current and five former 
smokers). Therefore, we expect that increasing the top dose, which was now arbitrarily 
chosen at 80 mg, could further reduce the number of false negatives and thus increase the 
test’s sensitivity even more. However, it cannot be ruled out that there may actually be 
subjects with asthma that remain unresponsive to even higher doses inhaled adenosine, which 
requires further investigation.  
 
The subjects did not appear to react more severely to dry powder adenosine than anticipated 
from their responsiveness to AMP, indicating that the test is safe to use. Severe cough, a side 
effect that has been shown to hinder applicability of the mannitol provocation test (10), 
another indirect measure of AHR, was only reported in one subject. No other side effects 
were observed. 
 
We previously reported that AHR to AMP is associated with eosinophilic inflammation (1). 
In the present study, blood eosinophils were included in the prediction models, although their 
individual contributions were not significant for either PC20 AMP or PD20 adenosine (p = 
0.066 and p = 0.11 respectively). This can be explained by the fact that in the present study 
we investigated eosinophilic inflammation in blood rather than sputum, by the smaller study 
population (60 vs. 120 patients (1)) and the non-parametric distribution due to the high 
number of non-responders, especially to AMP. Alternatively, differences in smoking behavior 
of the subjects may have played a role. Smoking has been shown to blunt eosinophilic 
inflammation, demonstrated by lower numbers of eosinophils in sputum and blood of smokers 
and ex-smokers compared to never-smokers (11). Further studies in never-smokers are 
therefore warranted. 
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In conclusion, we have shown that bronchial provocation with dry powder adenosine is a 
suitable alternative to provocation with nebulized AMP, considering the good agreement 
between the tests and comparable baseline predictors. Moreover, dry powder adenosine 
appears to offer an improvement over nebulized AMP, because of its higher sensitivity for 
less hyperresponsive subjects with asthma.  
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Figure 1: (A) Comparison of the PC20 AMP and PD20 adenosine. The lines indicate the 
geometric means, * depicts negative test results, which were censored to PC20 AMP = 640 
mg/mL and PD20 adenosine = 160 mg in the analyses. (B) Correlation analysis between PC20 
AMP and PD20 adenosine, showing a strongly significant correlation between the two test 
results (rSp = 0.799, p < 0.001). 
 
 
Table 1: Baseline predictors for PC20 AMP and PD20 adenosine obtained by multiple linear 
regression analysis. 
Dependent variable Baseline predictor B CI 95% p-value R
2
 
log2 PC20  
AMP 
Age (years) 0.111 0.035; 0.187 0.005 
0.34 
Smoking status -0.028 -1.82; 1.77 0.98 
Eos blood (% total) -0.306 -0.686; 0.074 0.11 
FEV1 (%pred) 0.047 -0.011; 0.104 0.11 
RV (%pred) -0.018 -0.054; 0.017 0.31 
Scond (/L) -1.94 -42.1; 38.2 0.92 
log2 PD20 
Adenosine 
Age (years) 0.059 0.007; 0.112 0.027 
0.30 
Eos blood (% total) -0.244 -0.542; 0.055 0.11 
FEV1 (%pred) 0.052 0.009; 0.096 0.020 
RV (%pred) -0.024 -0.050; 0.002 0.073 
PC20: provocative concentration causing a 20% drop in FEV1; PD20: provocative dose causing a 20% 
drop in FEV1; Eos blood: blood eosinophils as percentage of total leukocytes; FEV1: forced expiratory 
volume in 1 s; RV: residual volume; Scond: ventilation heterogeneity of the conductive lung zone. 
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